Eli Lilly develops and commercializes medicines for diabetes, obesity, oncology, and neuroscience. Leading products include Mounjaro and Zepbound for the treatment of type 2 diabetes and weight management. The company markets its pharmaceuticals to healthcare professionals and patients through established distribution channels in key markets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 15,558 | — | 5,661 | 60.4% |
| Q3 2025 | 17,600.8 | — | 5,582.5 | 425.4% |
| Q4 2025 | 19,292 | — | 6,637.7 | 38.7% |
| Q1 2026 | 19,799 | — | 7,396 | 146.6% |
| Q2 2026 | 22,974 | 47.7% | 7,095 | 25.3% |
All markets — KeepWinning global stock screener
Other companies on NYSE: JPMorgan Chase & Co. (JPM), Visa Inc. (V), ExxonMobil Holdings Corporation (XOM), Johnson & Johnson (JNJ), Mastercard Incorporated (MA), AbbVie Inc. (ABBV)